Functional HLA selection in haploidentical HCT for hematologic malignancies: a systematic review and meta-analysis
In brief
HLA-DRB1 mismatch tracks with 26% less relapse; HLA-B mismatch, 48% more non-relapse mortality
In a meta-analysis of 31 studies of haploidentical transplants for blood cancers, HLA-DRB1 mismatches in the graft-versus-host direction were associated with 26% lower relapse risk, while HLA-B leader mismatches were associated with 48% higher non-relapse mortality. The authors propose matching HLA-B leader first, then using selected DRB1 mismatches to improve leukemia control, but this selection strategy still needs testing.
- Journal
- Stem cell research & therapy (Q1)
- Published
- 24 August 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Shayan Forghani, Amirhossein Shahsavand, Ardin Damavandi Kamali, Arian Ghasemloo, Reza Samiee, Mohammadamin Kharaghani, et al.
- PMID
- 43053219
- DOI
- 10.1186/s13287-026-05263-3
Why clinicians should know about it
- Picked for Hematology (paper of the day, 21 November 2026): Meta-analysis informs functional HLA selection for haploidentical transplantation
Abstract
Optimal donor selection for haploidentical HCT remains undefined, often relying on structural matching paradigms derived from unrelated donor transplantation. We aimed to evaluate the prognostic value of Human Leukocyte Antigen (HLA) features regarding outcomes of hematopoietic cell transplantation (HCT). We performed a PRISMA 2020-compliant, PROSPERO-registered systematic review (CRD420251088497) of PubMed, Embase, Web of Science, and Cochrane. We included clinical studies of haploidentical HCT for hematologic malignancies evaluating HLA-related factors and transplant outcomes. Two reviewers independently screened, extracted data, and assessed quality (Newcastle-Ottawa Scale). Hazard ratios were pooled in R using inverse-variance meta-analysis with common or random effects models based on heterogeneity (I²). In this systematic review and meta-analysis of 31 studies, we identified distinct immunogenetic determinants of relapse and survival. HLA-DRB1 mismatches in the graft-versus-host direction were associated with a reduced risk of relapse (HR, 0.74; p < .001), an effect enhanced by concurrent HLA-DQB1 matching. In contrast, HLA-B leader mismatches were linked to inferior overall survival (HR, 1.24; p = .001) and higher non-relapse mortality (HR, 1.48; p < .001). Non-permissive HLA-DPB1 mismatches in the GVH direction were associated with improved disease-free survival without increasing acute GVHD. Advanced computational approaches, including eplet mismatch load, showed inconsistent associations with outcomes compared with locus-specific functional matching. These findings support shifting from allele counting to functional selection. We propose a hierarchical strategy: first, prioritize innate safety (matching HLA-B leader) to minimize NRM, then target adaptive efficacy (mismatching HLA-DRB1) to maximize graft-versus-leukemia effects.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.